

Madia Lozupone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3197255/publications.pdf>

Version: 2024-02-01

116
papers

4,013
citations

126708

33
h-index

138251

58
g-index

121
all docs

121
docs citations

121
times ranked

5918
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver frailty and all-cause mortality in the older participants of the Salus in Apulia Study. <i>GeroScience</i> , 2022, 44, 835-845.	2.1	12
2	Role of plant-based diet in late-life cognitive decline: results from the Salus in Apulia Study. <i>Nutritional Neuroscience</i> , 2022, 25, 1300-1309.	1.5	15
3	Processed meat consumption and the risk of incident late-onset depression: a 12-year follow-up of the Salus in Apulia Study. <i>Age and Ageing</i> , 2022, 51, .	0.7	5
4	The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy. <i>Psychiatry Research</i> , 2022, 308, 114346.	1.7	3
5	Mediterranean Diet and Fatty Liver Risk in a Population of Overweight Older Italians: A Propensity Score-Matched Case-Cohort Study. <i>Nutrients</i> , 2022, 14, 258.	1.7	5
6	Frailty and outcome after traumatic brain injury. <i>Lancet Neurology</i> , The, 2022, 21, 107-108.	4.9	6
7	Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210816.	1.1	8
8	Association of Neuroretinal Thinning and Microvascular Changes with Hypertension in an Older Population in Southern Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1098.	1.0	6
9	Role of Dietary Carotenoids in Frailty Syndrome: A Systematic Review. <i>Biomedicines</i> , 2022, 10, 632.	1.4	7
10	Dietary Patterns Associated with Diabetes in an Older Population from Southern Italy Using an Unsupervised Learning Approach. <i>Sensors</i> , 2022, 22, 2193.	2.1	11
11	Dietary Customs and Social Deprivation in an Aging Population From Southern Italy: A Machine Learning Approach. <i>Frontiers in Nutrition</i> , 2022, 9, 811076.	1.6	6
12	Clinical Indicators of Oral Frailty: A Domain-Specific Frailty Phenotype. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 2391-2394.	1.0	4
13	ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 759-771.	1.9	6
14	Motoric Cognitive Risk Syndrome, Subtypes and 8-Year All-Cause Mortality in Aging Phenotypes: The Salus in Apulia Study. <i>Brain Sciences</i> , 2022, 12, 861.	1.1	7
15	Retinal Vascular Density on Optical Coherence Tomography Angiography and Age-Related Central and Peripheral Hearing Loss in a Southern Italian Older Population. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 2169-2177.	1.7	6
16	Late-life depression and its impact on rehabilitation after traumatic injuries. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2313-2316.	1.4	2
17	Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 325-337.	0.9	2
18	Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy. <i>GeroScience</i> , 2021, 43, 1003-1014.	2.1	6

#	ARTICLE	IF	CITATIONS
19	Oral frailty and neurodegeneration in Alzheimer's disease. <i>Neural Regeneration Research</i> , 2021, 16, 2149.	1.6	34
20	Vitamin D in the development and progression of Alzheimer's disease: implications for clinical management. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 287-301.	1.4	9
21	Cognitive frailty. , 2021, , 463-476.		2
22	How gait influences frailty models and health-related outcomes in clinical-based and population-based studies: a systematic review. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 274-297.	2.9	52
23	Physical Frailty, Multimorbidity, and All-Cause Mortality in an Older Population From Southern Italy: Results from the Salus in Apulia Study. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 598-605.	1.2	53
24	Dietary Habits and Nutrient Intakes Are Associated to Age-Related Central Auditory Processing Disorder in a Cohort From Southern Italy. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 629017.	1.7	4
25	Physical and cognitive profiles in motoric cognitive risk syndrome in an older population from Southern Italy. <i>European Journal of Neurology</i> , 2021, 28, 2565-2573.	1.7	23
26	Association Between Central and Peripheral Age-Related Hearing Loss and Different Frailty Phenotypes in an Older Population in Southern Italy. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 561.	1.2	31
27	Oral frailty and its determinants in older age: a systematic review. <i>The Lancet Healthy Longevity</i> , 2021, 2, e507-e520.	2.0	89
28	COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1-7.	1.0	11
29	Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 127, 193-211.	2.9	54
30	Associations between nutritional frailty and 8-year all-cause mortality in older adults: The Salus in Apulia Study. <i>Journal of Internal Medicine</i> , 2021, 290, 1071-1082.	2.7	31
31	How many frailties exist? " Authors' reply. <i>The Lancet Healthy Longevity</i> , 2021, 2, e616.	2.0	1
32	Beverages Consumption and Oral Health in the Aging Population: A Systematic Review. <i>Frontiers in Nutrition</i> , 2021, 8, 762383.	1.6	21
33	Consumption of processed meat may increase the risk of incident late-onset depression. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119225.	0.3	0
34	Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study. <i>Biomedicine</i> , 2021, 9, 1617.	1.4	2
35	Could epigenetics play a role in suicidal behavior in older age?. <i>Epigenomics</i> , 2021, , .	1.0	1
36	Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12979.	1.2	6

#	ARTICLE	IF	CITATIONS
37	Liver Health and Dementia in an Italian Older Population: Findings From the Salus in Apulia Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 748888.	1.7	12
38	Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 919-933.	1.9	22
39	Frontal lobe syndrome and dementias. , 2020, , 617-632.		1
40	Age-related hearing loss and neuropathologic burden. <i>Neurology</i> , 2020, 95, 511-512.	1.5	8
41	Anti-amyloid- β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 319-335.	1.0	57
42	Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12065.	1.8	21
43	Nutritional domains in frailty tools: Working towards an operational definition of nutritional frailty. <i>Ageing Research Reviews</i> , 2020, 64, 101148.	5.0	43
44	Age-related hearing loss and speech perception disorder: the broken interface between healthcare professionals and older adults. <i>European Geriatric Medicine</i> , 2020, 11, 893-895.	1.2	4
45	The relationship between epigenetics and microbiota in neuropsychiatric diseases. <i>Epigenomics</i> , 2020, 12, 1559-1568.	1.0	11
46	A multidimensional frailty approach in predicting and preventing dementia. <i>The Lancet Healthy Longevity</i> , 2020, 1, e49-e50.	2.0	3
47	Social Frailty in the COVID-19 Pandemic Era. <i>Frontiers in Psychiatry</i> , 2020, 11, 577113.	1.3	20
48	Can pharmacotherapy effectively reduce Alzheimer's related agitation?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1517-1522.	0.9	4
49	Social determinants of late-life depression epigenetics. <i>Epigenomics</i> , 2020, 12, 559-562.	1.0	10
50	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 213-228.	4.9	73
51	Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study. <i>Nutrients</i> , 2020, 12, 426.	1.7	40
52	Traditional Dietary Patterns and Risk of Mortality in a Longitudinal Cohort of the Salus in Apulia Study. <i>Nutrients</i> , 2020, 12, 1070.	1.7	27
53	The association of patient-reported symptoms and clinical and lung function parameters in patients with chronic obstructive pulmonary disease in stable phase. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 637-643.	1.0	2
54	Age-Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 348-355.	1.1	39

#	ARTICLE	IF	CITATIONS
55	The Challenge of Antidepressant Therapeutics in Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1260, 267-281.	0.8	4
56	Delusions in dementias. , 2020, , 647-664.		0
57	Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging. <i>Alzheimer's and Dementia</i> , 2019, 15, 1019-1028.	0.4	47
58	Time to test antibacterial therapy in Alzheimer's disease. <i>Brain</i> , 2019, 142, 2905-2929.	3.7	89
59	Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 751-765.	1.5	0
60	Do anti-amyloid- β drugs affect neuropsychiatric status in Alzheimer's disease patients?. <i>Ageing Research Reviews</i> , 2019, 55, 100948.	5.0	24
61	Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 599-602.	1.4	32
62	The Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear. <i>Frontiers in Neuroscience</i> , 2019, 13, 619.	1.4	70
63	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1091-1107.	0.9	15
64	Episodic memory and learning rates in amyotrophic lateral sclerosis without dementia. <i>Cortex</i> , 2019, 117, 257-265.	1.1	9
65	Disease-modifying therapies for tauopathies: agents in the pipeline. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 397-408.	1.4	15
66	Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2019, 8, 4.	3.6	5
67	The Role of Biomarkers in Psychiatry. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1118, 135-162.	0.8	29
68	A critical appraisal of amyloid- β -targeting therapies for Alzheimer's disease. <i>Nature Reviews Neurology</i> , 2019, 15, 73-88.	4.9	666
69	Are antibodies directed against amyloid- β (A β) oligomers the last call for the A β hypothesis of Alzheimer's disease?. <i>Immunotherapy</i> , 2019, 11, 3-6.	1.0	50
70	Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231881100.	1.1	68
71	Understanding frailty to predict and prevent dementia. <i>Lancet Neurology</i> , The, 2019, 18, 133-134.	4.9	19
72	Amyloid- β immunotherapy for alzheimer disease: Is it now a long shot?. <i>Annals of Neurology</i> , 2019, 85, 303-315.	2.8	126

#	ARTICLE	IF	CITATIONS
73	Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke. <i>Drugs</i> , 2019, 79, 143-160.	4.9	38
74	Role of <i>CLU</i> , <i>PICALM</i> , and <i>TNK1</i> Genotypes in Aging With and Without Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 4333-4344.	1.9	19
75	Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer's Disease Versus Vascular Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 699-711.	1.2	17
76	Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 993-1012.	1.2	214
77	Comprehensive Geriatric Assessment in Long-Term Care and Nursing Homes. <i>Practical Issues in Geriatrics</i> , 2018, , 47-56.	0.3	0
78	Pharmacotherapy for the treatment of depression in patients with Alzheimer's disease: a treatment-resistant depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 823-842.	0.9	43
79	Genetics of tailored medicine: Focus on CNS drugs. <i>Microchemical Journal</i> , 2018, 136, 164-169.	2.3	1
80	An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities. <i>Rejuvenation Research</i> , 2018, 21, 3-14.	0.9	25
81	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	1.4	34
82	<i>CYP2D6</i> genotypes in revolving door patients with bipolar disorders. <i>Medicine (United States)</i> , 2018, 97, e11998.	0.4	26
83	<i>BACE</i> inhibitors in clinical development for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 847-857.	1.4	66
84	Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 95, 480-498.	2.9	27
85	Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 989-1000.	1.2	42
86	Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S229-S254.	1.2	38
87	Contribution of Mediterranean Diet in the Prevention of Alzheimer's Disease. , 2018, , 139-155.		3
88	<i>Klotho</i> Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder. <i>Molecular Neurobiology</i> , 2017, 54, 1340-1351.	1.9	28
89	Emerging biomarkers and screening for cognitive frailty. <i>Ageing Clinical and Experimental Research</i> , 2017, 29, 1075-1086.	1.4	39
90	Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 121-130.	1.2	41

#	ARTICLE	IF	CITATIONS
91	Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 89.e1-89.e8.	1.2	126
92	Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 815-849.	1.2	249
93	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1373-1385.	1.0	8
94	Cognitive frailty: a potential target for secondary prevention of dementia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1023-1027.	1.5	40
95	Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. <i>Expert Review of Proteomics</i> , 2017, 14, 809-824.	1.3	36
96	Evaluation of Cognitive Dysfunction in a Sample of Patients Affected by Bipolar Disorder. <i>European Psychiatry</i> , 2017, 41, S212-S212.	0.1	0
97	Swallowing Disturbances and Psychiatric Profile in Older Adults: The GreatAGE Study. <i>European Psychiatry</i> , 2017, 41, S173-S173.	0.1	0
98	Educational level influenced the gold standard diagnosis of late-life depression in the GreatAGE study. <i>European Psychiatry</i> , 2017, 41, S173-S173.	0.1	1
99	Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 1236-1248.	0.6	90
100	Bipolar Disorder, Obesity and Cognitive Impairment. <i>European Psychiatry</i> , 2017, 41, S207-S207.	0.1	4
101	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 259-277.	1.5	13
102	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. <i>BioMed Research International</i> , 2016, 2016, 1-15.	0.9	138
103	Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1357-1369.	1.4	10
104	Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?. <i>International Psychogeriatrics</i> , 2016, 28, 1111-1124.	0.6	19
105	Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 973-979.	1.2	23
106	Emerging drugs to reduce abnormal β -amyloid protein in Alzheimer's disease patients. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 377-391.	1.0	54
107	Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. <i>Immunotherapy</i> , 2016, 8, 1119-1134.	1.0	61
108	The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 431-442.	0.4	6

#	ARTICLE	IF	CITATIONS
109	High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 843-846.	1.5	10
110	Tau-directed approaches for the treatment of Alzheimerâ€™s disease: focus on leuco-methylthioninium. Expert Review of Neurotherapeutics, 2016, 16, 259-277.	1.4	35
111	Tau aggregation inhibitors: the future of Alzheimerâ€™s pharmacotherapy?. Expert Opinion on Pharmacotherapy, 2016, 17, 457-461.	0.9	17
112	Progresses in treating agitation: a major clinical challenge in Alzheimerâ€™s disease. Expert Opinion on Pharmacotherapy, 2015, 16, 2581-2588.	0.9	43
113	Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis. Clinical and Experimental Medicine, 2015, 15, 65-72.	1.9	27
114	Metabolic Syndrome: Differences between Psychiatric and Internal Medicine Patients. International Journal of Psychiatry in Medicine, 2013, 45, 203-226.	0.8	14
115	Genetically Determined Measures of Striatal D2 Signaling Predict Prefrontal Activity during Working Memory Performance. PLoS ONE, 2010, 5, e9348.	1.1	82
116	Biopsychosocial Frailty and the Risk of Incident Dementia. The Italian Longitudinal Study of Aging. SSRN Electronic Journal, 0, , .	0.4	0